Roche divarasib shows superior results against older KRAS inhibitors in lung cancer trials
Roche reported positive data for its drug divarasib at the European Society for Medical Oncology meeting regarding second-line advanced non-small cell lung cancer.
Drug performance compared to competitors
The study focused on patients with G12C KRAS mutations who had already received prior treatment. Roche found that divarasib outperformed older inhibitors from Amgen and Bristol Myers Squibb in this specific setting. This comparison highlights the drug's potential advantage over existing options for advanced cases.
Conference context and future plans
The European Society for Medical Oncology meeting concluded with these findings presented to attendees. Organizers noted that this represents one of the more impressive data sets from the year. A virtual recap event is scheduled for Thursday at 10 a.m. Eastern time.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.